Interview with Safia Rizvi, Managing Director, UCB India
You have only recently been appointed Managing Director for the first time in your career. How did your first year with UCB India go so far? My first year at…
Address: 504, Peninsula TowersPeninsula Corporate ParkGanpatrao Kadam Marg, Lower ParelIND – Mumbai 400 013,India
Tel: +91 22 40 49 11 11
Web: http://www.ucb.com/india/
At UCB our sense of purpose is to help people suffering from severe central nervous system or immunological disorders lead normal, everyday lives. Our ambition is to offer them innovative new medicines and ground-breaking solutions that go beyond the drug. We are committed to enabling cutting-edge scientific research that is driven by the patients’ needs.
UCB, headquartered in Brussels, Belgium, is a global biopharma company with a team of over 8500 talented employees, a strong market presence in more than 40 countries, € 3.2 billion in revenue (2010) and numerous strategic partnerships across the industry.
We combine biology and chemistry to make major breakthroughs.
By integrating our expertise in large, antibody-based molecules and small, chemically-derived molecules, we can offer families with severe diseases and their specialist physicians the advantages of both large and small molecules to produce extraordinary breakthroughs.
We partner with the leaders in the pharmaceutical industry.
The complexities of severe diseases are beyond the expertise and resources of a single organisation. That is why we have teamed up with partners – we play to our strengths and tap into the organisations with greater or complementary strengths.
UCB’s medicines are making a real difference to the lives of people all over the world. Some of our products are among the leaders in their field.
Vimpat® (lacosamide)
Epilepsy
Keppra® (levetiracetam)
Epilepsy
Neupro® (rotigotine)
Parkinson’s disease
Restless Legs Syndrome
Nootropil® (piracetam)
Regulating cerebral functions
Metadate CD™ (methylphenidate HCl) (CII)
Attention Deficit Hyperactivity Disorder (ADHD)
Cimzia® (certolizumab pegol)
Crohn’s disease
Rheumatoid arthritis
Xyzal® (levocetirizine)
Allergies
Zyrtec® (cetirizine)
Allergies
Tussionex™ (hydrocodone polistirex and chlorpheniramine polistirex) (CIII)
Respiratory disease
You have only recently been appointed Managing Director for the first time in your career. How did your first year with UCB India go so far? My first year at…
Cachet Pharmaceuticals was founded in 1978, what have been your main achievements? We started as a manufacturing company. In the early 1990s we started our own marketing and since then…
With almost EUR 9bn turnover and more than 22,000 people worldwide, Royal DSM has truly grown into an MNC. Within the global market, there is no doubt that India has…
You have very successfully executed a vision that you have had for the company since it was a 200 Rs Cr turnover, India-focused enterprise 15 years ago. You have had…
When Astellas announced to expand its presence in India in 2009, you were already speaking of the company’s long commitment and solid relationship with India. Can you elaborate on these…
What probably best explains the contrasts in the Indian pharmaceutical landscape is the fact that India can take many shapes and forms and that different companies in India will keep…
For decades now, ACG has been building up its reputation in the global pharma space. The Indian Pharma industry, at the same time, increasingly is catching up with the Western…
For decades now, ACG has been building up its reputation in the global pharma space. The Indian Pharma industry, at the same time, increasingly is catching up with the Western…
You already joined the company in 2001, and returned after an MBA in the USA in 2004. This was also the time the company really took off, as you subsequently…
Watson is one the largest generic players in the US but the international presence of the company is still relatively modest. Watson does not have commercial operations in India but…
You already joined the company in 2001, and returned after an MBA in the USA in 2004. This was also the time the company really took off, as you subsequently…
The managing director of Encube Ethicals discusses contract manufacturing in India today, growing competition from China, and partnering with the world’s leading multinational pharma companies. Mr Dilip Shah from…
You already joined the company in 2001, and returned after an MBA in the USA in 2004. This was also the time the company really took off, as you subsequently…
See our Cookie Privacy Policy Here
